摘要
Tumor necrosis factor(TNF)inhibitors have improved a lot the treatment of numerous diseases,with the well-known example of rheumatoid arthritis(RA).In the early 2000s,postmarketing data quickly revealed an alarming number of severe tuberculosis(TB)under such treatment.These findings were consistent with previous results in mice where TNF is essential for lymph node formation and granuloma organization.The effects of TNF inhibition on RA synovium structure are very similar to those on granuloma,with changes in cellular interactions,cytokine,and chemokine production.In addition to the role of TNF in granuloma,the interleukin(IL)-12/interferon(IFN)-γpathway is required for an efficient host defense against TB.Primary and secondary immunodeficiencies affecting this pathway lead to severe bacillus Calmette-Guérin(BCG)reaction or full TB.Any chronic inflammation as in RA induces a systemic Th1 defect that predisposes to TB through specific downregulation of the IL-12Rß2 chain.When TNF inhibitors are initiated,this transiently increases this risk of TB,through effects on cellular interactions in a latent TB granuloma.At a later stage,when a better control disease activity is obtained,the risk of TB is reduced but not abrogated.Given the clear benefit from TNF inhibition,latent TB infection screening at baseline is essential for an optimal safety.
基金
supported in part by the IHU OPERA.This review is based on a talk given during the 17th International Congress of Immunology that took place on 19-23 October 2019 in Beijing,China。
